The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
PEDMARQSI Norgine Pty Ltd
Product name
PEDMARQSI
Sponsor
Accepted date
Jan-2025
Active ingredients
sodium thiosulfate anhydrous
Proposed indication
PEDMARQSI is for the prevention of damage to certain parts of the ear that is sometimes caused by cisplatin chemotherapy. PEDMARQSI is to be used in children aged 1 month to under 18 years with localised solid tumours that have not spread to other parts of the body.
Application type
C (new indication)
Publication date
Jan-2025